(glatiramer acetate) 40mg
Three Times Weekly
Copaxone® 40mg three times weekly is indicated for the treatment of relapsing forms of multiple sclerosis. It is not indicated for primary or secondary progressive forms of multiple sclerosis (see Section 5.1 of the Summary of Product Characteristics).1
The recommended dosage in adults is Copaxone® 40mg (one pre-filled syringe), administered as a subcutaneous injection three times a week with at least 48 hours apart.1
Copaxone® 40mg three times weekly provides significant reductions in relapse rates, which is consistent with Copaxone® 20mg.2
A lower incidence of injection site reactions in comparison to Copaxone® 20mg2-5
The overall safety profile is comparable with Copaxone® 20mg.2
Copaxone® comes in a prefilled syringe which is compatible with CSYNCTM.
The CSYNCTM has an ergonomic design and well positioned button for easy injection. Its audio and visual indicators also provide patients reassurance of dose delivery.
Patients should be instructed in self-injection techniques and should be supervised by a healthcare professional the first time they self-inject and for 30 minutes after.1
A different site should be chosen each day, so this will reduce the chances of any irritation or pain. Sites for self-injection include abdomen, arms, hips and thighs.1
1mL of solution for injection contains 40mg glatiramer acetate*, equivalent to 36mg of glatiramer base per pre-filled syringe.1
Glatiramer acetate is the acetate salt of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine and L-lysine, in molar fraction ranges of 0.129-0.153, 0.392-0.462, 0.086-0.100 and 0.300-0.374, respectively. The average molecular weight of glatiramer acetate is in the range of 5,000-9,000 Daltons.1For a full list of excipients, see Section 6.1. of the Summary of Product Characteristics.
Teva Pharmaceuticals Ltd
Marketing Authorisation Number(s)
1 Copaxone® (glatiramer acetate) 40mg Summary of Product Characteristics.
2 Khan O et al. Ann Neurol 2013: 73; 705–713.
3 Johnson KP et al. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268–1276.
4 Comi G et al. Ann Neurol 2011; 69: 75–82.
5 Comi G et al. European-Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290–297.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.